NCT07090655View on ClinicalTrials.gov

A Phase 1 Study of Budoprutug (TNT119) Subcutaneous and Intravenous Injections in Normal Healthy Volunteers

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

August 11, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

June 30, 2026

Conditions
Healthy Volunteers
Interventions
DRUG

Budoprutug

Subcutaneous or IV administration

DRUG

Placebo

Placebo comparator

Trial Locations (1)

Unknown

RECRUITING

Nucleus Network Brisbane, Brisbane

Sponsors

Lead Sponsor

Climb Bio, Inc.
All Listed Sponsors
lead

Climb Bio, Inc.

INDUSTRY